Oncoc4
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9640 Medical Center Dr, Rockville, Maryl...Website
www.oncoc4.comRevenue
$28.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Oncoc4
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases.Explore more
Oncoc4 Org Chart
Get the full picture
Sign in to uncover key details.
JW
Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncoc4 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Oncoc4 is spiking on competitors!
Check if Oncoc4 has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Oncoc4 launches new products
Funding: Get notified immidiatlly once Oncoc4 has new funding data
Congratulate Masked Content for being promoted to Masked Content at Oncoc4
Earning: See what the market has to say on Oncoc4 recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Oncoc4, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Oncoc4 had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Oncoc4 as Masked Content
Find more new buyers
Compare Similar Companies to Oncoc4
Compare insights from companies similar to Oncoc4, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oncoc4 is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oncoc4 is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oncoc4.
Oncoc4 financials insights
Gather financial insights about Oncoc4, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$50M
Oncoc4 Tech Stack
A closer look at the technologies used by Oncoc4
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Oncoc4 News & Media
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLCChina's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)
Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype of lung cancer Breakthrough Therapy designation will allow for an expedited development and regulatory review of gotistobart in China Global pivotal PRESERVE-003 Phase 3 clinical trial in squamous non-small cell lung cancer Is Ongoing ROCKVILLE, Md., Oct. 27, 2025 /PRNewswire/ -- OncoC4 announced today that China's National Medical Product AdGoodwin Represents OncoC4 In Closing Nearly $50 Million In Series B Financing - Mondaq
The Life Sciences team represented OncoC4, Inc. in the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund...OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates
ROCKVILLE, Md., Oct. 2, 2025 /PRNewswire/ -- OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by additional capital from the Company's co-founders and...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncoc4
Sign Up For FreeTo access detailed company insights
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immun... Read More
